Sulfonamide derivatives with benzothiazole scaffold: Synthesis and carbonic anhydrase I–II inhibition properties
MakaleYalnız künye
Özet
The secondary sulfonamide derivatives containing benzothiazole scaffold (1–10) were synthesized to determine their inhibition properties on two physiologically essential human carbonic anhydrases isoforms (hCAs, EC, 4.2.1.1), hCA I, and hCA II. The inhibitory effects of the compounds on hCA I and hCA II isoenzymes were investigated by comparing their IC50 and Ki values. The Ki values of compounds (1–10) against hCA I and hCA II are in the range of 0.052 ± 0.022–0.971 ± 0.280 and 0.025 ± 0.010–0.682 ± 0.335, respectively. Some of these inhibited the enzyme more effectively than the standard drug, acetazolamide. In particular, compounds 5 and 4 were found to be most effective on hCA I and hCA II.
Anahtar Kelimeler
RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/gumushane/11970Resmi atıflarda kullanılan kalıcı adresTam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Öztürk, Cansu | |
| dc.contributor.author | Kalay, Erbay | |
| dc.contributor.author | Gerni, Serpil | |
| dc.contributor.author | Balci, Neslihan | |
| dc.contributor.author | Tokali, Feyzi Sinan | |
| dc.contributor.author | Aslan, Osman Nuri | |
| dc.contributor.author | Polat, Emrah | |
| dc.date.accessioned | 2026-10-22T10:19:32.890636631Z | |
| dc.date.available | 2026-10-22T10:19:32.890636631Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | The secondary sulfonamide derivatives containing benzothiazole scaffold (1–10) were synthesized to determine their inhibition properties on two physiologically essential human carbonic anhydrases isoforms (hCAs, EC, 4.2.1.1), hCA I, and hCA II. The inhibitory effects of the compounds on hCA I and hCA II isoenzymes were investigated by comparing their IC50 and Ki values. The Ki values of compounds (1–10) against hCA I and hCA II are in the range of 0.052 ± 0.022–0.971 ± 0.280 and 0.025 ± 0.010–0.682 ± 0.335, respectively. Some of these inhibited the enzyme more effectively than the standard drug, acetazolamide. In particular, compounds 5 and 4 were found to be most effective on hCA I and hCA II. | |
| dc.identifier.doi | 10.1002/bab.2534 | |
| dc.identifier.eissn | 1470-8744 | |
| dc.identifier.endpage | 231 | |
| dc.identifier.issn | 0885-4513 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmid | 37964505 | |
| dc.identifier.scopus | 2-s2.0-85176960132 | |
| dc.identifier.startpage | 223 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/gumushane/11970 | |
| dc.identifier.volume | 71 | |
| dc.identifier.wos | WOS:001102034900001 | |
| dc.language.iso | en | |
| dc.publisher | John Wiley and Sons Inc | |
| dc.relation.ispartof | Biotechnology and Applied Biochemistry | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | benzothiazole moiety | |
| dc.subject | human carbonic anhydrase I | |
| dc.subject | human carbonic anhydrase II | |
| dc.subject | inhibition | |
| dc.subject | secondary sulfonamide derivatives | |
| dc.subject.classification | Biochemistry & Molecular Biology | |
| dc.subject.classification | Biotechnology & Applied Microbiology | |
| dc.subject.other | Benzothiazoles | |
| dc.subject.other | Carbonic Anhydrase I | |
| dc.subject.other | Carbonic Anhydrase Inhibitors | |
| dc.subject.other | Humans | |
| dc.subject.other | Molecular Structure | |
| dc.subject.other | Structure-Activity Relationship | |
| dc.subject.other | Sulfanilamide | |
| dc.subject.other | Sulfonamides | |
| dc.subject.other | Scaffolds | |
| dc.subject.other | Sulfur compounds | |
| dc.subject.other | acetazolamide | |
| dc.subject.other | benzothiazole derivative | |
| dc.subject.other | carbonate dehydratase I | |
| dc.subject.other | carbonate dehydratase II | |
| dc.subject.other | carbonate dehydratase inhibitor | |
| dc.subject.other | sulfonamide | |
| dc.subject.other | Benzothiazole moiety | |
| dc.subject.other | Human carbonic anhydrase I | |
| dc.subject.other | Human carbonic anhydrase II | |
| dc.subject.other | Human carbonic anhydrases | |
| dc.subject.other | Inhibition | |
| dc.subject.other | Inhibition property | |
| dc.subject.other | Secondary sulphonamide derivative | |
| dc.subject.other | Sulfonamide derivatives | |
| dc.subject.other | Synthesised | |
| dc.subject.other | Article | |
| dc.subject.other | carbon nuclear magnetic resonance | |
| dc.subject.other | controlled study | |
| dc.subject.other | drug binding site | |
| dc.subject.other | drug purification | |
| dc.subject.other | drug synthesis | |
| dc.subject.other | electron | |
| dc.subject.other | enzyme inhibition | |
| dc.subject.other | human | |
| dc.subject.other | human cell | |
| dc.subject.other | IC50 | |
| dc.subject.other | liquid chromatography-mass spectrometry | |
| dc.subject.other | proton nuclear magnetic resonance | |
| dc.subject.other | structure activity relation | |
| dc.subject.other | substitution reaction | |
| dc.subject.other | chemical structure | |
| dc.subject.other | metabolism | |
| dc.subject.other | Carbonic anhydrase | |
| dc.title | Sulfonamide derivatives with benzothiazole scaffold: Synthesis and carbonic anhydrase I–II inhibition properties | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.openalex | 13 | |
| rdl.citation.scopus | 13 | |
| rdl.citation.wos | 11 | |
| rdl.department | Siran Dursun Keles Vocational School of Health Services, Gümüshane University, Gümüshane, Turkey | |
| rdl.oa.status | closed | |
| rdl.sdg | SDG03 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |

